The recent U.S. Food and Drug Administration (FDA) approvals of two next-generation transcatheter aortic valve replacements (TAVR) devices will transform the U.S. market for TAVR procedures over the next decade, according to an analyst with research and consulting firm GlobalData.
Two companion papers published in Academic Emergency Medicine address the question of when it is appropriate to discharge patients experiencing a potentially fatal blood clot. The studies particularly focus on patients presenting with low-risk deep vein thrombosis (DVT) or pulmonary embolism (PE).
Insulin resistance affects tens of millions of Americans and is a big risk factor for heart disease. Yet, some people with the condition never develop heart disease, while some experience moderate coronary blockages. Others, though, get severe atherosclerosis – multiple blockages and deterioration of coronary arteries characterized by thick, hard, plaque-ridden arterial walls. Researchers at the University of North Carolina (UNC) School of Medicine created a first-of-its-kind animal model to pinpoint two biomarkers that are elevated in the most severe form of coronary disease.
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
A new study proves race and gender-related disparities exist in care for patients who have recently been diagnosed with atrial fibrillation (AF). The study, published in the July edition of HeartRhythm, the official journal of the Heart Rhythm Society (HRS), includes data from more than 500,000 Medicare beneficiaries. Results notably indicate that female patients compared to male patients are less likely to receive oral anticoagulation, a medication used to lower the likelihood of experiencing a stroke. Women are also less likely than men to receive an ablation, as were Hispanics versus whites.
Boston Scientific has initiated a study of the company's first fully resorbable drug-eluting scaffold system. The Fully Absorbable Scaffold Feasibility Study (FAST) is a prospective, single-arm study designed to assess the safety and performance of this next-generation scaffold for the treatment of atherosclerotic coronary lesions.
Veryan Medical announced that the first subject has been enrolled in their MIMICS-2 study at Universitäts-Herzzentrum Freiburg in Bad Krozingen, Germany by the European principal investigator, Prof. Thomas Zeller.
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
Hospitals in the Midwest were more likely than others to refer patients for guideline-recommended cardiac rehabilitation following angioplasty, according to new original research. This is possibly because more rehab programs are available in the region.
Building teams that include advanced practice providers can help cardiovascular practices meet the challenges of modern practice, according to a new health policy statement by the American College of Cardiology (ACC). These challenges include workforce shortages, an aging patient population with growing complexities in care and a payment system in transition.
NeoStem Inc. presented updated efficacy and safety results from the one-year follow-up for its Phase 2 PreSERVE study and additional analyses of certain functional tests at the American College of Cardiology’s 64th annual scientific session and expo in March. The one-year follow-up results are defined as all data accumulated until the last patient enrolled completed 12-month follow-up. Thus, the results actually represent data from patients with a median follow-up of 18 months.
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
Medtronic plc announced the first in-office implant of its miniaturized cardiac monitor as part of the Medtronic Reveal LINQ In-Office 2 (RIO 2) Study. One of the world's smallest cardiac monitors, the Reveal LINQ insertable cardiac monitor (ICM) was successfully implanted in an office setting at Scripps Clinic in La Jolla, California, by cardiologist John Rogers, M.D. The RIO 2 study will determine if the procedure, performed in an in-office setting, is as safe as procedures performed in a traditional hospital setting — such as an operating room, cardiac catheterization laboratory or electrophysiology laboratory.
Medtronic plc announced that its Protege GPS self-expanding peripheral stent system has received approval from the U.S. Food and Drug Administration (FDA) for the treatment of stenotic lesions of the common and external iliac arteries.
Vital Images Inc. will debut its U.S. Food and Drug Administration (FDA) 510(k)-cleared CT Myocardial Perfusion application at the 10th annual scientific meeting of the Society of Cardiovascular Computed Tomography (SCCT). The meeting will be held in Las Vegas July 16-19.
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
Infinitt announced today that it has entered into a seven-year Partner Plus Agreement with TridentUSA Health Services based on an unlimited software licensing model for Infinitt PACS and Cardiology Suite, in addition to custom software development. The contract also encompasses Infinitt's embedded voice recognition and reporting software, as well as the new Gx Communicator package (Critical Results, Peer Review and Collaborator Instant Messaging).
Konica Minolta Medical Imaging announced new Blue Moon Lifecycle Solutions designed to help customers minimize downtime, maximize productivity, and eliminate risk for the lifetime of their handheld Sonimage P3 and portable Sonimage HS1 ultrasound systems. The company will introduce the new Blue Moon Lifecycle Solutions at the Association for Medical Imaging Management (AHRA) annual meeting, July 20-22 in Las Vegas.
Thoratec announced that the HeartMate PHP (Percutaneous Heart Pump) received CE Mark approval, permitting sale in the European Union and other international countries. Approval was based on data from the first 30 patients enrolled in the HeartMate PHP SHIELD I CE Mark Trial examining use of PHP to support patients undergoing a high-risk percutaneous coronary intervention (PCI) procedure. Data from all 50 patients enrolled in this study will be presented later in 2015.